VYNE News and Press, VYNE Therapeutics Inc Com From 10/28/21

BRIDGEWATER, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the third quarter ended September 30, 2021, on Wednesday, November 10, 2021, before ...

VYN201 exhibits anti-inflammatory effect in preclinical data similar to a super-potent glucocorticosteroid VYN201 appeared well-tolerated in mice, as seen through animal body weight and skin condition VYN201 also demonstrates stronger inhibition of key Th17 cytokines in ex vivo da...

Renowned Experts to Support VYNE’s Strategy of Developing Novel Treatments for Immunological and Inflammatory diseases SAB to Help Guide Clinical Development of VYNE’s BET Inhibitor Drug Candidates BRIDGEWATER, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- VYNE The...

Important milestone achieved as part of the Company’s new corporate strategy to develop treatments for immuno-inflammatory diseases Topline results anticipated in early Q1 2022 BRIDGEWATER, N.J., Oct. 19, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ( ...

BRIDGEWATER, N.J., Oct. 05, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the first patient has been enrolled in a Phase 3 study in China evaluating AMZEEQ® (minocycline) topical foam, 4% in mod...

BRIDGEWATER, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the Cantor Fitzgerald Virtual Global Healthcare Conference , t...

BRIDGEWATER, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference to be...

Last week, there were three significant developments with respect to ADMA. The market has taken these events to be bearish for ADMA's outlook, with the stock selling off this week. I, however, remain very bullish on ADMA. For further details see: ADMA Biologics: Recent S...

Image source: The Motley Fool. VYNE Therapeutics Inc. (NASDAQ: VYNE) Q2 2021 Earnings Call Aug 12, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: VYNE Therapeutics Inc. (VYNE) Q2 2021 Earnings Call Transcript

VYNE Therapeutics Inc. (VYNE) Q2 2021 Earnings Conference Call August 12, 2021 08:30 AM ET Company Participants Chase Oswald - Investor Relations, LifeSci Advisors Dave Domzalski - President & Chief Executive Officer Tyler Zeronda - Chief Financial Officer Iain Stuart - Chief Scientific O...